BioWorld

May 5, 2004

View Archived Issues

ODAC In Favor Of Safety Trials For Amgen, J&J EPO Products

GAITHERSBURG, Md. - The Oncologic Drugs Advisory Committee generally agreed that it is reasonable to ask makers of Aranesp and Procrit to conduct placebo-controlled trials to assess possible adverse events. (BioWorld Today) Read More

Acologix's Series B Pulls Down $39.6M For Bone Drug Phase II

Read More

Microbia Completes $40M Round As Lead Compounds Near Clinic

Read More

Merrimack Raises $28M To Fund Development Of Network Biology

Read More

Serono Secures Rights To 4SC Program In Autoimmune Disease

Read More

Axonyx Brings In Another $20M Through Sale Of Stock, Warrants

Read More

Other News To Note

Read More